Shares of Incyte Corp. rallied 4.13% to $59.22 Monday, on what proved to be an all-around favorable trading session for the ...

Incyte (Nasdaq: INCY) announced today that it has scheduled its first quarter financial results conference call and webcast ...

Incyte Corp. closed 32.26% below its 52-week high of $83.95, which the company achieved on November 8th.

Incyte Corp. closed 34.28% below its 52-week high of $83.95, which the company achieved on November 8th.

After a legal decision delayed its entry last fall, Sun Pharma has received the all-clear to tap into the U.S. | After Sun ...

The awards were made under the Company’s 2024 Inducement Stock Incentive Plan, with a grant date and vesting commencement ...

Piotr Swat / SOPA Images / LightRocket / Getty Images Incyte shares sank Monday after the drugmaker released the latest data from a clinical trial. The drug, povorcitinib, accomplished its goal of ...

A Federal Circuit panel looked likely to reverse a district court’s order blocking Sun Pharmaceutical Industries Ltd. from ...

Incyte's infringement lawsuit is claiming that Sun Pharma's drug infringes a US patent (No. 9,662,335) it holds on the use of ...

UBS lowered the firm’s price target on Incyte (INCY) to $61 from $69 and keeps a Neutral rating on the shares. The stock has held up since the ...

Stay updated with the latest news on Times of India. Get all the trending City News, India News, Business News, and Sports News. For Entertainment News, TV News, and Lifestyle Tips, visit Etimes.